Sign in
4

Changes in Ownership

UNITED THERAPEUTICS Corp Filed Acc 0001673232-25-000010

PRESIDENT AND COO sold 22,500 shares at an average $429.25 ($9,658,073)

  • PRESIDENT AND COO acquired 22,500 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

BENKOWITZ MICHAEL · PRESIDENT AND COO

Table I: Non-derivative

13 lines
Date Transaction Shares Price Value Owned after D/I
2025-11-03 Exercise or conversion : show line 1 in the form 10b5-1 +14,625 $135.42 $1,980,518 14,625 I
2025-11-03 Sale : show line 2 in the form 10b5-1 −964 $432.55 $416,976 13,661 I
2025-11-03 Sale : show line 3 in the form 10b5-1 −2,687 $433.52 $1,164,868 10,974 I
2025-11-03 Sale : show line 4 in the form 10b5-1 −2,918 $434.68 $1,268,407 8,056 I
2025-11-03 Sale : show line 5 in the form 10b5-1 −3,204 $435.52 $1,395,391 4,852 I
2025-11-03 Sale : show line 6 in the form 10b5-1 −2,121 $436.45 $925,707 2,731 I
2025-11-03 Sale : show line 7 in the form 10b5-1 −890 $437.70 $389,551 1,841 I
2025-11-03 Sale : show line 8 in the form 10b5-1 −585 $438.34 $256,427 1,256 I
Open-market sales · 22,500 sh · avg $429.25 · $9,658,073

Table II: Derivative

2 lines
Date Transaction Shares Exercise Expires Underlying Owned after D/I
2025-11-03 Exercise or conversion : show line 14 in the form 10b5-1 Stock Options −14,625 $135.42 2026-03-15 14,625 41,250 I
2025-11-03 Exercise or conversion : show line 15 in the form 10b5-1 Stock Options −7,875 $146.03 2026-03-15 10,500 10,500 I
Loading xslF345X05/primarydocument.xml…